Bio Essence Corp (BIOE) stock

BIOEOTCPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/30

$0.42+0.03 (+7.72%)

Close on Oct 19, 2026Market cap $22.70MP/E 10.5Yield –

Bio Essence operating margin

Operating margin is operating income as a percentage of revenue.

Bio Essence's operating margin for the twelve months ending Sep 30, 2026 was 45.1%. For fiscal 2025 it was 47.4%, against -141.8% the year before. The highest annual figure on record is 47.4% in fiscal 2025.

Annual operating margin

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	47.4%	+189.3
FY2024	Dec 31, 2024	-141.8%	−79.2
FY2023	Dec 31, 2023	-62.7%	+19.6
FY2022	Dec 31, 2022	-82.2%	+14.3
FY2021	Dec 31, 2021	-96.6%	−9.7
FY2020	Dec 31, 2020	-86.8%	–

Quarterly operating margin

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q3 FY2026	Sep 30, 2026	-62.9%	−73.3
Q2 FY2026	Jun 30, 2026	35.1%	+11.5
Q1 FY2026	Mar 31, 2026	43.1%	+967.4
Q4 FY2025	Dec 31, 2025	69.6%	+67.0
Q3 FY2025	Sep 30, 2025	10.4%	+119.1
Q2 FY2025	Jun 30, 2025	23.6%	+419.4
Q1 FY2025	Mar 31, 2025	-924.3%	−871.2
Q4 FY2024	Dec 31, 2024	2.6%	+19.2
Q3 FY2024	Sep 30, 2024	-108.7%	−101.6
Q2 FY2024	Jun 30, 2024	-395.8%	−427.8
Q3 FY2023	Sep 30, 2023	-53.1%	+47.2
Q2 FY2023	Jun 30, 2023	-16.6%	+37.5
Q1 FY2023	Mar 31, 2023	-7.1%	+66.8
Q4 FY2022	Dec 31, 2022	32.0%	+125.3
Q3 FY2022	Sep 30, 2022	-100.3%	−15.3
Q2 FY2022	Jun 30, 2022	-54.1%	+56.6
Q1 FY2022	Mar 31, 2022	-73.9%	+22.6
Q4 FY2021	Dec 31, 2021	-93.3%	+56.9
Q3 FY2021	Sep 30, 2021	-85.0%	−3.0
Q2 FY2021	Jun 30, 2021	-110.8%	−15.1
Q1 FY2021	Mar 31, 2021	-96.5%	−57.2
Q4 FY2020	Dec 31, 2020	-150.2%	–
Q3 FY2020	Sep 30, 2020	-82.0%	–
Q2 FY2020	Jun 30, 2020	-95.7%	–
Q1 FY2020	Mar 31, 2020	-39.3%	–